UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 AND 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of February 2013
File No. 000-54598
Stellar Biotechnologies Inc.
(Name of Registrant)
332 E. Scott Street, Port Hueneme, CA 93041
(Address of principal executive offices)
Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
FORM 20-F __X__
FORM 40-F ______
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ___
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ___
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Form 6-K to be signed on its behalf by the undersigned, thereunto duly authorized.
Stellar Biotechnologies Inc.
(Registrant)
Dated: February 20, 2013 | By: /s/ "Darrll Brookstein" Darrell Brookstein Director |
Exhibits:
99.1
News Release dated February 20, 2013
STELLAR BIOTECHNOLOGIES REPORTS ON ANNUAL GENERAL AND SPECIAL MEETING
PORT HUENEME, CA (February 20, 2013) -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH) announces that it held its Annual General and Special Meeting of Shareholders (the “Meeting”) on Tuesday, February 12, 2013 at which Meeting all resolutions were approved. The resolutions passed at the Meeting include the following:
1.
The number of directors for the ensuing year was set at six.
2.
The following individuals were elected directors of the Company: Gregory T. Baxter, Darrell H. Brookstein, David L. Hill, Daniel E. Morse, Frank R. Oakes and Mayank (Mike) Sampat.
2.
D&H Group LLP, Chartered Accountants, were re-appointed as auditors of the Company.
3.
Disinterested shareholders approved the grant of an aggregate of 735,557 options under the existing stock option plan to insiders of the Company that exceeded the 10% limit reserved for insiders at the date of grant.
4.
A special resolution authorized the alteration of the Company’s Notice of Articles and Articles to amend and increase the authorized share structure of the Company, to authorize an unlimited number of Preferred Shares without par value, issuable in series, with special rights and restrictions applicable to the Preferred Shares which permit the directors to affix specific rights and restrictions to each series if, as and when issued.
The Board of Directors appointed the following officers of the Company for the ensuing year:
Frank R. Oakes
President and Chief Executive Officer
Darrell Brookstein
Executive VP – Corporate Development and Finance and Corporate Secretary
Scott Davis
Chief Financial Officer
Herbert S. Chow
Chief Technology Officer
Catherine Brisson
Chief Pharmaceutical Officer
Mayank (Mike) Sampat, David L. Hill and Frank R. Oakes were re-appointed members of the Audit Committee for the ensuing year, of which Mayank (Mike) Sampat is Chair.
About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX VENTURE: KLH) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH). KLH is an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. Potent, yet proven safe in humans, KLH operates as both a vital component for conjugate vaccines (targeting cancer, autoimmune, and infectious diseases) as well as an antigen for measuring immune status. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high-quality, GMP-grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need. To receive regular updates, enter email at bottom of http://stellarbiotechnologies.com/investors/news_releases/
Forward Looking Statements
There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.
Contact Information
•
Contacts:
Stellar Biotechnologies, Inc.
Darrell Brookstein
Executive VP, Corporate Development and Finance
Email: dbrookstein@stellarbiotech.com
Frank Oakes
Chairman
foakes@stellarbiotech.com
Main +1 (805) 488-2800
Investor Relations:
MZ Group
Mark A. McPartland
Senior Vice President
Phone: 1 212-301-7130
Email: markmcp@mzgroup.us
Web: www.mzgroup.us